重磅研究之一:贝伐单抗治疗新诊断胶质母细胞瘤的III期双盲安慰剂对照试验
RTOG 0825:贝伐单抗治疗新诊断胶质母细胞瘤的III期双盲安慰剂对照试验。结论:新诊断的GBM 使用BEV此外并没有改善OS,数据显示虽然PFS有所提高,但没有达到显著性标准。考虑到II期临床试验的显著疗效,专家在解读这一结果时认为,应当尝试检验贝伐单抗与其他药物联用的疗效。
摘要详情:
Molecular predictors of and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
Background: Chemoradiation (CRT) with temozolomide (TMZ/RT→TMZ) is the standard of care for newly diagnosed GBM. This trial determined if the addition of Bev to standard CRT improves survival (OS) or progression-free survival (PFS) in newly diagnosed GBM.
Methods: This phase III trial was conducted by the RTOG, NCCTG, and ECOG. Neurologically stable pts > 18 yrs with KPS ≥ 60, and > 1cm3 tumor tissue block, were randomized to Arm 1: standard CRT + placebo or Arm 2: standard CRT plus Bev (10 mg/kg iv q 2wks). Experimental treatment began at wk 4 of radiation then thru 6-12 cycles of maintenance chemotherapy. Protocol specified co-primary endpoints were OS and PFS, with significance levels of .023 and .002, respectively. At progression, treatment was unblinded and pts allowed to crossover or continue Bev. Symptom, QOL and neurocognitive (NCF) testing was performed in the majority of pts. Secondary analyses evaluated impact of MGMT methylation (meth) and prognostic 9 gene signature status.
Results: From 978 registered pts, 637 were randomized. Inadequate tissue (n=105) and blood on imaging (n=40) were key reasons for non-randomization. No difference was found between arms for OS (median 16.1 vs. 15.7 mo, p = 0.11). PFS was extended for Arm 2 (7.3 vs. 10.7 mo, p = 0.004). Pts with MGMT meth had superior OS (23.2 vs. 14.3 mo, p < 0.001) and PFS (14.1 vs. 8.2 mo, p < 0.001). Neither the 9 gene signature nor MGMT predicted selective benefit for Bev treatment, but best prognosis pts (MGMT meth, favorable 9-gene), had a worse survival trend with Bev (15.7 vs 25 mo p = 0.08). To date, 128 pts were unblinded on Arm 1 (salvage Bev in 86) and 87 pts on Arm 2 (continued Bev in 39). Increased grade ≥ 3 toxicity was seen with Bev, mostly neutropenia, hypertension, and DVT/PE.
Conclusions: The addition of Bev for newly diagnosed GBM did not improve OS, did improve PFS but did not reach the significance criterion. MGMT and 9 gene profile did not identify selective benefit, but risk subset results suggested strongly against the upfront use of Bev in the best prognosis pts. Full interpretation of the PFS results incorporating symptom burden, QOL, and NCF is ongoing. Support: NCI U10 CA 21661, U10 CA37422, and Genentech. Clinical trial information: NCT00884741.
- ASCO2013:复旦大学附属肿瘤医院杜祥教授发现新型生物标记物可用于弥漫大B细胞淋巴瘤分子分型及预后
- ASCO2013:一线治疗之Nintedanib对索拉非尼的头对头临床试验
- ASCO2013:二线治疗之Regorafenib的三期临床试验
- ASCO2013:一线治疗之索拉非尼上市后的临床监测
- ASCO2013:流行病学之性别对肝癌患者生存的关系
- ASCO2013:流行病学之糖尿病是罹患肝癌的独立危险因素
- ASCO2013:观察性研究之乙肝相关肝癌和丙肝相关肝癌的VEGF通路相关分子的表达对比
- ASCO2013:标志物之VEGF及VEGFR的基因多态性与索拉非尼治疗毒性及疗效的相关
- ASCO2013:二线治疗之PF-03446962 (ALK-1单抗)的1期临床研究
- ASCO2013:一线/二线治疗之TGF-β抑制剂(LY2157299)